CureVac N.V. (NASDAQ:CVAC) Q3 2023 Earnings Conference Call November 14, 2023 9:00 AM ET

Company Participants

Sarah Fakih - VP, Corporate Communications and IR

Alexander Zehnder - CEO

Pierre Kemula - CFO

Myriam Mendila - CDO

Marcus Dalton - Head, Intellectual Property

Conference Call Participants

Evan Wang - Guggenheim

Ellie Merle - UBS

Eun Yang - Jefferies

Charlie Yang - Bank of America

Operator

Greetings and welcome to the CureVac Financial Results for Third Quarter and First Nine Months of 2023 Business Update. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Sarah Fakih, Vice President Corporate Communications and Investor Relations. Thank you. Sarah, you may begin.

Sarah Fakih

Thank you. Good morning, good afternoon, and welcome to our conference call. My name is Sarah Fakih and I'm the Vice President of Corporate Communications and Investor Relations at CureVac. Please let me introduce today's speakers.

On the call with me from CureVac are Alexander Zehnder, Chief Executive Officer of CureVac; Myriam Mendila, our Chief Development Officer; and Pierre Kemula, Chief Financial Officer of CureVac. Our Head of Intellectual Property, Marcus Dalton will be present for the Q&A session.

Please note that this call is being webcast live and will be archived on the Events & Presentations section under Investor Relations on our website.

Before we begin, a few forward-looking statements. The discussions and responses to your questions on this call reflect management's view as of today, Tuesday, November 14th, 2023. We will be making statements and providing responses to your questions that state our intentions, beliefs, expectations, or predictions of the future. These constitute forward-looking statements for the purpose of the Safe Harbor provisions.

These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. CureVac disclaims any intention or obligation to revise any forward-looking statements. For more information, please refer to our filings with the US Securities and Exchange Commission.

I will now turn the call over to Alexander.

Alexander Zehnder

Thank you, Sarah. Ladies and gentlemen, good morning, good afternoon to everyone on the webcast. As another year of strong performance draws to a close, we continue to successfully maintain our forward momentum in the clinical development programs in infectious diseases as well as in oncology, and we are delivering on our strategic priorities.